Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast NEO, a new predictive test within its Ataraxis Breast platform designed to estimate the likelihood of pathologic complete response (pCR) following neoadjuvant therapy in patients with early-stage breast cancer.
Ataraxis Breast NEO can be ordered from the core needle biopsy pathology slide collected at initial diagnosis, before any treatment decision is made. From that single specimen, clinicians receive a patient-specific treatment response likelihood across all major breast cancer subtypes, including HER2-positive and triple-negative breast cancer, the populations most likely to receive neoadjuvant therapy and for whom pCR is most clinically meaningful. The test was developed using multimodal data from over 1,000 breast cancer patients worldwide and clinically validated in over 1,500 patients across several observational real-world studies and prospective clinical trials.
Response to neoadjuvant therapy has a major impact on long-term outcomes and physicians’ decisions around surgical and systemic treatment. Many patients who achieve a pathologic complete response have significantly better survival outcomes than non-responders. Yet today, the decision to pursue neoadjuvant therapy and the selection of the right treatment regimen are largely guided by population-level response rates that vary widely depending on molecular profile, regimen, and disease stage. Given that an increasing number of neoadjuvant therapy options are becoming available for breast cancer patients, it is becoming more challenging and important to identify in advance which patients are more or less likely to respond to neoadjuvant therapy. Ataraxis Breast NEO was built to answer that question.
“With the launch of Ataraxis Breast NEO, we have expanded our ability to help breast cancer patients not just in the adjuvant setting, but also in the neoadjuvant setting. Ultimately, we want Ataraxis Breast to become the platform that can answer all important questions about therapy selection for breast cancer patients and personalize the entire treatment plan from the very beginning.” – Jan Witowski, MD, PhD, CEO and co-founder of Ataraxis AI
The Ataraxis Breast Suite
Ataraxis Breast NEO is a new capability available in the Ataraxis Breast suite, expanding on already available prognostic Ataraxis Breast RISK (individualized recurrence risk) and predictive Ataraxis Breast CTX (individualized adjuvant chemotherapy benefit). Ataraxis’s tests combine digitized H&E pathology slides with clinical data to generate patient-specific predictions.
Together, NEO, RISK, and CTX form a connected suite of AI-powered tests that support individualized decision-making at every stage of early-stage breast cancer care. For the first time, clinicians have a single platform that can inform treatment planning from initial biopsy through adjuvant therapy, without exhausting tissue or requiring extended wait times.
About Ataraxis AI
Ataraxis AI is a precision oncology company building AI-powered tools to personalize cancer care. By integrating routine digital pathology with clinical data, Ataraxis aims to deliver individualized insights into prognosis and treatment benefit across multiple cancer types.
Ataraxis™ Breast is Ataraxis AI’s flagship multimodal platform for breast cancer. Delivered as a suite of AI-powered clinical tests, it combines routine digital pathology with clinical data to generate predictions of recurrence risk and therapy response, supporting decision-making across the full continuum of care. The Ataraxis Breast platform was developed using 20,000+ multimodal patient cases and is designed to fit into existing pathology workflows without requiring additional tissue or specialized assays. All Ataraxis Breast tests are offered as laboratory-developed tests through a CLIA-certified laboratory. To learn more, visit ataraxis.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409921421/en/
Media gallery
